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Physicians seem increasingly skeptical of the results of
randomized clinical trials. The reasons are multifactorial but
might be due, in part, to concerns about generalizability and
reproducibility of trial results. Contemporary cardiology
trials routinely involve thousands of patients and hundreds
of sites in multiple countries/continents, making them
challenging to design, operationally complex to execute, and
difficult to oversee (1). Recent clinical trials in cardiovascular
medicine have been criticized by regulatory agencies, due to
perceived high rates of subjects who are lost to follow-up or
off study drug. In response, the Food and Drug Adminis-
tration has released new guidance emphasizing the impor-
tance of patient retention and the need for innovation and
improvement in site monitoring (2).
See page 571
The very insightful study by Butler et al. (3) in this issue
of the Journal adds several interesting observations related to
the quality of clinical trials in the current era. The authors
analyzed the EVEREST (Efficacy of Vasopressin Antago-
nism in Heart Failure: Outcome Study with Tolvaptan) trial
that was performed in 4,133 patients hospitalized with
decompensated heart failure at 436 sites. Overall, the trial
found tolvaptan to have no effect on either all-cause mor-
tality or cardiovascular death/hospital stay for heart failure
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Association functional class III/IV heart failure, ejection
fraction 40%, randomized within 48 h of admission to
the hospital with heart failure), 77 sites (18%) were
unable to enroll a single patient, and 224 sites (51%)
enrolled 10 patients. Among the 359 participating sites
that did enroll patients, only 30 sites were able to enroll
30 subjects. Only 1.8% of North American sites and
1.3% of Western European sites were considered to be
high-enrolling sites. In contrast, 20% of South American
sites and 27% of Eastern European sites enrolled 30
subjects, illustrating the current challenges randomized
trials have in enrolling patients from Western European
and North American countries.
The authors went on to perform a post hoc analysis
evaluating the relationship between the number of pa-
tients enrolled/site and clinical outcomes in the trial.
They found that patients at high-enrolling sites (30
subjects) had better clinical outcomes than those patients
enrolled at intermediate- (11 to 30 subjects) or low-
enrolling (10 subjects) sites. Furthermore, these high-
enrolling sites had the highest proportion of patients who
completed the protocol, whereas lower-enrolling sites
had more subjects who withdrew consent or were lost to
follow-up.
The differential in clinical outcomes between patients at
high- versus intermediate- and low-enrolling sites is likely
explained by fundamental differences in the patient popu-
lations. Patients from low-enrolling sites on average were
older with lower ejection fraction, longer QRS duration,
lower blood pressure, higher B-type natriuretic peptide,
higher creatinine, more likely to have an implantable
cardioverter-defibrillator previously placed, and more likely
to be treated with inotropes upon admission. Yet, even after
these factors were controlled in multivariable models, high-
enrolling sites had better outcomes.
This study is not the first study to describe outcome
differences in subgroups or even variability in treatment
effect found in a randomized clinical trial. In particular,
geographic variation in treatment effect has been seen in
multiple randomized clinical trials and has been well-
described (5,6,7). However, the present findings with regard
to the association of site enrollment volume and outcome
were independent of any effect of region.
Are the findings of heterogeneity in outcomes on the
basis of site enrollment troublesome? It is quite possible that
the improved outcomes seen at high-enrolling sites are
predominately due to the enrollment of lower-acuity pa-
tients. For this reason, further studies are necessary from
other clinical trials to determine whether similar relation-
ships are present, because the interplay between high
volume, high quality, and improved outcomes has been
shown in many clinical settings (8). It remains possible that
the differences shown between high- and low-enrolling sites
might be due to the actual quality of sites participating in
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there is considerable variability in the quality of sites
participating in clinical trials. Underreporting of safety and
efficacy endpoints, inadequate concomitant therapy, and
high patient discontinuation rates are just a few examples
of recent site-specific issues seen in trials. These issues
were the impetus for recent Food and Drug Administra-
tion guidance providing support for flexible monitoring
plans that are able to adjust and provide further monitoring
support and oversight to sites that seem to be lagging in
quality. Yet, to date, there remains no standardized way in
which to measure the quality of a research site in general.
It is not inconceivable that the differential outcomes
seen between low- and high-enrolling sites could affect
the overall results and interpretation of the trial. How-
ever, the randomization process, which used block ran-
domization within each center, should have been robust
enough that patients on and off study drug would be
equally distributed between sites of potentially differing
quality (9). This is supported statistically by the lack of a
treatment interaction in the multivariable modeling. Of
greater concern are the implications for randomized
clinical trials moving forward.
Is it possible to minimize inter-site differences while at
the same time improving site-based quality and outcomes?
As a specialty, cardiology has taken great pride in its focus
on evidenced-based medicine. Yet, the majority of recom-
mendations found in our guidelines are not supported by
randomized trials but rather by expert opinion, illustrating
the tremendous opportunities for continued research (10).
We have lagged behind specialties such as oncology that
have formed large clinical trial networks that enroll patients
into appropriate clinical trials.
The National Heart, Lung, and Blood Institute has worked
to bring this type of focus to cardiology with initiatives such as
the Heart Failure Clinical Research Network, and efforts
should be made to expand this model to different disease states
within cardiology (11,12). As physicians, we must develop and
advocate for improved clinical trial networks and encourage
enrollment and appropriate follow-up. Registries and compar-
ative effectiveness techniques offer the ability to study questions
that are unable to be answered with clinical trials (13), although
observational research alone has been shown on multiple
occasions to be flawed (14). Thus, the development and
promotion of a culture of scientific inquiry in which random-
ized trials are part of routine clinical practice would provide a
tremendous opportunity to advance cardiovascular medicineand simultaneously improve care for all patients with cardio-
vascular disease.
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